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Cholesterol Lowering or Pleiotropic Effects?Filippo Crea, MD, Giampaolo Niccoli, MD, PHDSEE PAGE 495S econdary prevention of cardiovascular eventsin patients with documented coronary arterydisease is an unmet need. Current guidelines
recommend tight control of cardiovascular risk fac-
tors (1). In this context, lowering of low-density lipo-
protein cholesterol (LDL-C) remains crucial, because
it has been associated with better prognosis and sta-
bilization, or even regression of coronary atheroscle-
rosis as assessed by intravascular ultrasound (IVUS).
Many studies have suggested that targeting LDL-C
to levels to <70 mg/dl should be the goal of statin
therapy in high-risk patients. In the meta-analysis
by the Cholesterol Treatment Trialists’ Collaboration,
which included 5 trials that compared more versus
less intensive statin therapy, on-treatment LDL-C
levels were reduced 39 to 77 mg/dl by the more inten-
sive regimens, which is an average of approximately
20 mg/dl lower than the less intensive regimens (2).
This further LDL-C reduction was associated with a
highly signiﬁcant 15% decrease in major cardiovascu-
lar events, without increasing the risk of cancer or
noncardiovascular mortality.
For the many patients who do not achieve
guideline-driven LDL-C targets with statin mono-
therapy, guidelines recommend either increasing the
statin dose or initiating statin therapy in combination
with another lipid-lowering agent. In particular, the
new American College of Cardiology/American Heart
Association guidelines (3) recommend that the
maximum tolerated statin dose be used in high-risk
individuals, and that the addition of a nonstatin
cholesterol-lowering drug may be considered if the*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Institute of Cardiology, Catholic University of the Sacred Heart,
Rome, Italy. Both authors have reported that they have no relationships
relevant to the contents of this paper to disclose.risk-reduction beneﬁt outweighs the safety risk in
patients with a less than adequate therapeutic
response to statins.
The beneﬁcial effects of intensive statin treatment
are attributed to the slowing of atherosclerotic plaque
progression, and more importantly, to plaque stabi-
lization, as suggested by large IVUS studies of more
versus less intensive statin therapy (4,5).In this issue of the Journal, Tsujita et al. report the
results of the PRECISE-IVUS (Plaque Regression With
Cholesterol Absorption Inhibitor or Synthesis Inhibi-
tor Evaluated by Intravascular Ultrasound) trial (6).
Brieﬂy, patients with stable angina or an acute coro-
nary syndrome were randomized to either atorvas-
tatin alone (monotherapy group) or atorvastatin
plus ezetimibe (combination therapy group), with
the atorvastatin dosage up-titrated to achieve an
LDL-C <70 mg/dl. IVUS was performed at baseline
and at 9- to 12-month follow-up. Patients randomized
to combination therapy experienced a greater reduc-
tion in percent atheroma volume (PAV) than those
randomized to monotherapy; the prevalence of side
effects was similar in the 2 groups.
At ﬁrst glance, the lower mean LDL-C level ach-
ieved with combination therapy than with mono-
therapy (63.2 mg/dl vs. 73.3 mg/dl) seems to account
for the enhanced regression associated with the
former. However, linear regression analysis failed to
show an association between achieved LDL-C levels
and PAV changes. Furthermore, in the SATURN
(Study of Coronary Atheroma by Intravascular Ultra-
sound: Effect of Rosuvastatin versus Atorvastatin)
trial, rosuvastatin 40 mg achieved lower levels of
LDL-C (mean 62.6 mg/dl) versus atorvastatin 80 mg
(mean 70.2 mg/dl), which were values very similar to
those observed in PRECISE-IVUS but had no detect-
able PAV reduction (7). Thus, cholesterol lowering
itself does not seem to explain the greater reduction
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Various mechanisms mediate the beneﬁcial effects of statins and ezetimibe on plaque
growth. CC ¼ cholesterol crystals; LDL-C ¼ low-density lipoprotein cholesterol;
vSMC ¼ vascular smooth muscle cells.
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509of PAV with combination therapy versus mono-
therapy observed in the PRECISE-IVUS trial.
This difference is unlikely to be accounted for by
the anti-inﬂammatory effect of ezetimibe. In the
PRECISE-IVUS trial, reduction of C-reactive protein
levels was similar in the 2 treatment groups. This
ﬁnding is in keeping with previous studies that
suggested no further reduction of inﬂammatory
biomarkers when ezetimibe was added to statin
therapy (8).
We would like to offer a possible explanation for
the greater reduction of PAV observed with combi-
nation therapy, which might stimulate further
research in this ﬁeld.
Ezetimibe acts at the brush border of the small
intestine, where it selectively inhibits both choles-
terol and plant sterol absorption from the intestinal
lumen into the enterocytes by selective blockage of
the sterol transporter, the Niemann–Pick C1-like
1 protein, thus eventually reducing their serum
levels (9). Accordingly, in PRECISE-IVUS, sterols
(lathosterol, campesterol, and sitosterol) and their
ratio to cholesterol decreased with the combination
therapy, but increased with monotherapy. Interest-
ingly, the campesterol-to-cholesterol ratio reduction
was signiﬁcantly and positively related to a reduction
in PAV, which suggested a possible role for sterols
other than cholesterol. The genetic disease sitoster-
olemia, which is characterized by elevated plasma
levels of plant sterol, is associated with premature
atherosclerosis, although the relationship between
plant sterols and atherosclerosis is not clear.
The largest prospective trials and genome-wide as-
sociation studies have suggested that high plasma
levels of plant sterols are associated with increased
risk, but other studies have reported no such associ-
ation or even an inverse relationship (10). Thus,
available data cannot conﬁrm an increased cardio-
vascular risk with plant sterols, but cannot rule it
out either (11). Only a prospective interventional
trial to analyze the effects of plant sterol–enriched
food on the incidence of cardiovascular events can
exclude a potential cardiovascular risk linked with
their excess.
Other pleiotropic effects unrelated to cholesterol
lowering might also be involved in ezetimibe-
related potentiation of plaque regression, including
modulation of genes related to inﬂammation and/or
oxidative stress (12), inhibition of monocyte and/or
macrophage differentiation by altering micro-
ribonucleic acid expression (13), and inhibition of
smooth muscle cell proliferation (14). Furthermore,
ezetimibe inhibits platelet aggregation and activa-
tion (15), and seems to modulate atheroscleroticplaque composition with reduction of cholesterol
crystals that, in turn, are associated with inﬂam-
masome activation, plaque growth, and vulnera-
bility (16,17). Ezetemibe and statins might have
additive effects on cholesterol crystallization (18)
(Figure 1).
In conclusion, the investigators of the PRECISE-
IVUS trial should be congratulated for this excellent
study, which provides a solid pathophysiological
foundation for the modest, albeit statistically sig-
niﬁcant, clinical beneﬁt observed with ezetemibe
plus simvastatin versus simvastatin alone in the
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial) (19). The molec-
ular mechanisms driving the additional beneﬁt of
ezetemibe on plaque progression compared with
statin monotherapy need to be further investigated.
In particular, it would be interesting to establish the
clinical relevance of the potential pleiotropic effects
of ezetemibe that operate beyond cholesterol
lowering.
The reality is always more complex than we tend to
believe, in line with the wise words of Isaac Newton:
“What we know is a drop, what we ignore is an
ocean.”
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